Morgan Stanley analyst Laura Sanchez maintains TPI Composites (NASDAQ:TPIC) with a Equal-Weight and lowers the price target from $24 to $23.
Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been
